Evidence map›Paper›PMID 33956350›Full record

ArticleThe Prostate2021

Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.

Jianfeng Xu, William B Isaacs, Mufaddal Mamawala, Zhuqing Shi, Patricia Landis, Jacqueline Petkewicz, Jun Wei, Chi-Hsiung Wang, W Kyle Resurreccion, Rong Na and 6 more

Open access · greenAbstract read
In one paragraph

Article in The Prostate, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.Virchows Archiv : an international journal of pathology · 2024
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Jianfeng XuProgram for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA.ORCID 0000-0002-9419-6627
William B IsaacsThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-6599-6775
Mufaddal MamawalaThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Zhuqing ShiProgram for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA.ORCID 0000-0001-6321-950X
Patricia LandisThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Jacqueline PetkewiczProgram for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA.
Jun WeiProgram for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA.
Chi-Hsiung WangProgram for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA.
W Kyle ResurreccionProgram for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA.
Rong NaProgram for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA.ORCID 0000-0001-7470-5108
Yasin BhanjiThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Kristian NovakovicProgram for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA.
Patrick C WalshThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
S Lilly ZhengProgram for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA.
Brian T HelfandProgram for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois, USA.
Christian P PavlovichThe Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
NorthShore University HealthSystem · USJohns Hopkins University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is characterized by its tendency to be multifocal. However, few studies have investigated the endogenous factors that explain the multifocal disease. The primary objective of the current study is to test whether inherited PCa risk is associated with multifocal tumors in PCa patients.

methodsSubjects in this study were PCa patients of European ancestry undergoing active surveillance at Johns Hopkins Hospital (N = 805) and NorthShore University HealthSystem (N = 432). The inherited risk was measured by genetic risk score (GRS), an odds ratio-weighted and population-standardized polygenic risk score based on known risk-associated single nucleotide polymorphisms. PCa multifocality was indirectly measured by the number and laterality of positive tumor cores from a 12-core systematic biopsy.

resultsIn the combined cohort, 35.7% and 66.3% of patients had ≥2 tumor cores at the initial diagnostic biopsy and on at least one subsequent surveillance biopsy, respectively. For tumor laterality, 7.8% and 47.8% of patients had bilateral tumor cores at diagnostic and surveillance biopsies, respectively. We found, for the first time, that patients with higher numbers of positive cores at diagnostic and surveillance biopsies, respectively, had significantly higher mean GRS values; p = .01 and p = 5.94E-04. Additionally, patients with bilateral tumors at diagnostic and surveillance biopsies, respectively, had significantly higher mean GRS values than those with unilateral tumors; p = .04 and p = .01. In contrast, no association was found between GRS and maximum core length of tumor or tumor grade at diagnostic/surveillance biopsies (all p > .05). Finally, we observed a modest trend that patients with higher GRS quartiles had a higher risk for tumor upgrading on surveillance biopsies. The trend, however, was not statistically significant (p > .05).

conclusionsThe associations of GRS with two measurements of PCa multifocality (core numbers and laterality) provide novel and consistent evidence for the link between inherited PCa risk and multifocal tumors.

Indexed as

AgedCohort StudiesHumansMaleMiddle AgedMultifactorial InheritancePolymorphism, Single NucleotideProstatic NeoplasmsRisk FactorsWatchful Waitingactive surveillancegenetic risk scorepositive coresprostate cancer

Identifiers

PMID33956350
PMCPMC8827243
OpenAlexW3159193101

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.